Precipio, Inc. (NASDAQ:PRPO) Short Interest Down 14.3% in June

Precipio, Inc. (NASDAQ:PRPO) was the target of a significant decline in short interest in June. As of June 15th, there was short interest totalling 1,200 shares, a decline of 14.3% from the May 31st total of 1,400 shares. Currently, 0.1% of the company’s shares are sold short. Based on an average daily trading volume, of 4,200 shares, the days-to-cover ratio is currently 0.3 days.

Precipio Trading Up 3.7 %

Shares of NASDAQ PRPO traded up $0.19 during trading on Monday, reaching $5.38. The stock had a trading volume of 1,490 shares, compared to its average volume of 5,452. Precipio has a fifty-two week low of $4.65 and a fifty-two week high of $8.99. The company has a debt-to-equity ratio of 0.01, a quick ratio of 0.62 and a current ratio of 0.78. The business’s 50-day moving average price is $5.74 and its 200-day moving average price is $6.13. The company has a market cap of $7.91 million, a P/E ratio of -1.57 and a beta of 1.41.

Precipio (NASDAQ:PRPO) last released its earnings results on Tuesday, May 14th. The biotechnology company reported ($1.46) EPS for the quarter. Precipio had a negative return on equity of 46.12% and a negative net margin of 31.00%. The company had revenue of $3.43 million for the quarter.

About Precipio

Precipio, Inc, a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; and HemeScreen, a suite of robust genetic diagnostic panels.